Search
Esophageal Candidiasis
go.drugbank.com/conditions/DBCOND0040096Synonyms: Candidiasis: [OS NOS] or [granuloma] or [intestinal] or [oesophageal] or [rectal])Motixafortide
go.drugbank.com/drugs/DB14939ApprovedInvestigational[A261476] Motixafortide was approved by the FDA in September 2023, in combination with filgrastim, for use in stem cell mobilization prior to autologous stem cell transplant in patients with multiple … [L48116] When administered alongside [filgrastim], another agent used to aid in stem cell collection, motixafortide enabled the collection of an adequate number of stem cells in ~92% of patients within
Aminoglutethimide
go.drugbank.com/drugs/DB00357ApprovedWithdrawnAminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties. … (From Martindale, The Extra Pharmacopoeia, 30th ed, p454)
Trichophyton mentagrophytes
go.drugbank.com/drugs/DB10446ApprovedTrichophyton mentagrophytes extract is used in allergenic testing.
Mixtures: Trichophyton for Intradermal Skin TestingrPSGL-Ig
go.drugbank.com/drugs/DB06256InvestigationalRecombinant P-selectin glycoprotein ligand IgG fusion protein (rPSGL-Ig) is a fusion protein of human P-selectin ligand and IgG1-Fc.
Synonyms: rPSGL-Ig, rPSGL-1-IgGancotamab
go.drugbank.com/drugs/DB14784InvestigationalGancotamab is under investigation in clinical trial NCT02213744 (MM-302 Plus Trastuzumab vs. … Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients).
Belapectin
go.drugbank.com/drugs/DB15125InvestigationalBelapectin is under investigation in clinical trial NCT02575404 (GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients).
Categories: Complex MixturesTrofinetide
go.drugbank.com/drugs/DB06045Approved[A258453] Trofinetide is marketed as DAYBUE and DAYBUE STIX in the United States, as DAYBUE in Canada, and as DAYBU in the European Union. … , making trofinetide the first and only treatment approved for Rett syndrome in the European Union.
VidPrevtyn Beta
go.drugbank.com/drugs/DB16427Approved[A245829,L49696] In October 2022, VidPrevtyn Beta was approved in the European Union for use as a booster dose in patients who have previously received a COVID-19 vaccine.[L49691] … [L49691] It comprises a recombinant SARS-CoV-2 spike protein (B.1.351 strain) - produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from
Categories: Complex MixturesTarloxotinib
go.drugbank.com/drugs/DB14944InvestigationalTarloxotinib is under investigation in clinical trial NCT03743350 (NSCLC Exon 20 or HER2-activating Mutations).